OncoLinkTV: ESMO 2002

Last Modified: January 31, 2003


Welcome to the Power of the Combination Media Workshop

This site has been developed by OncoLink as an information resource on current and critical issues affecting the treatment of cancer.

Every year 10 million new cases of cancer are diagnosed globally, only a third of which can be effectively treated. Combination therapy, however is promising to become the cornerstone for cancer treatments, offering patients improved response rates and tolerability. Phase III clinical data, to be presented at the media briefing discusses the role of Gemzar® based therapies in increasing treatment effectiveness and how they are one of the tools necessary to transform cancer from an acute to a chronic and manageable disease.

This webcast is based on information presented at the Power of the Combination Media Workshop conducted at the European Society for Medical Oncology congress in Nice, France, October 19, 2002.

In order to view this webcast, you will need Windows Media Player and Microsoft Internet Explorer or Netscape Navigator 4.X. Please see our help page for further information.



ACE Reporter Award (also see ACE Reporter Award - 2003)
Alberto Costa, Director of The European Society of Medical Oncology, will announce The launch of the ACE Reporter Award
Lynn Faulds Wood, UK broadcast journalist and bowel cancer survivor, will present The impact of the media on cancer patients.

Dr. Jorge Otero
Medical Director of the Gemzar Product Team
Eli Lilly and Company
10:50Gemzar: The history, the progress, the future
Dr. Lucio Crino
Bellaria Hospital
Bologna, Italy
11:10Gemzar: Innovative Combinations for Optimal Cancer Care
Dr. Christian Manegold
Professor of Medicine, University of Heidelberg
Thoraxklinik-Heidelberg GmbH, Germany
11:30Question & Answer Session
Chaired by Dr. Christian Manegold

For additional news about novel cancer treatments please see these articles:

Phase III single-blinded study of premexetred + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma

Pemetrexed performs well in metastatic breast cancer trials

Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG)

Supported by an unrestricted educational grant from Eli Lilly and Company.